Dermatofibrosarcoma protuberans (DFSP) is an uncommon soft tissue tumor. In children, there are acquired and congenital presentations. Due to clinical similarities with other conditions, diagnosis may be delayed.
Objective:
To review the clinical characteristics and treatment of DFSP in pediatric patients.
Methods:
A retrospective chart review was performed from January 2002 to September 2012. Inclusion criteria were patients under 18 years of age with a histopathologic diagnosis of DFSP. Data on demographics, clinical characteristics, treatments, and outcomes were collected.
Results:
Information was gathered from 17 patients; 9 (53%) were female. Congenital lesions were reported in 7 patients. The mean delay of diagnosis was 5.7 years; the most common anatomic location was the trunk in 8 of 17 (47%) cases. Treatment options included wide local surgery, Mohs surgery, and imatinib mesylate.
Conclusion:
A detailed medical history and identification of the natural course of common conditions seen in pediatric patients are important to identify less common lesions and to suspect DFSP.
Get full access to this article
View all access options for this article.
References
1.
McKeePHFletcherCD. Dermatofibrosarcoma protuberans presenting in infancy and childhood. J Cutan Pathol1991;18:241–6, doi:10.1111/j.1600-0560.1991.tb01230.x.
2.
PackGTTabahEJ. Dermato-fibrosarcoma protuberans. A report of 39 cases. AMA Arch Surg1951;62:391–411, doi:10.1001/archsurg.1951.01250030397008.
3.
RouhaniPFletcherCDDevesaSS. Cutaneous soft tissue sarcoma incidence patterns in the U.S.: an analysis of 12,114 cases. Cancer2008;113:616–27, doi:10.1002/cncr.23571.
4.
CheckettsSRHamiltonTKBaughmanRD. Congenital and childhood dermatofibrosarcoma protuberans: a case report and review of the literature. J Am Acad Dermatol2000;42 (5Pt 2):907–13, doi:10.1016/S0190-9622(00)90270-6.
5.
LoebDMThorntonKShokekO. Pediatric soft tissue sarcomas. Surg Clin North Am2008;88:615–27, doi:10.1016/j.suc.2008.03.008.
6.
KornikRIMuchardLKTengJM. Dermatofibrosarcoma protuberans in children: an update on the diagnosis and treatment. Pediatr Dermatol2012;29:707–13, doi:10.1111/j.1525-1470.2012.01767.x.
7.
GooskensSLOranjeAPvan AdrichemLN. Imatinib mesylate for children with dermatofibrosarcoma protuberans (DFSP). Pediatr Blood Cancer2010;55:369–73, doi:10.1002/pbc.22494.
8.
LoveWEKeilerSATamburroJE. Surgical management of congenital dermatofibrosarcoma protuberans. J Am Acad Dermatol2009;61:1014–23, doi:10.1016/j.jaad.2009.05.028.
9.
TaylorHBHelwigEB. Dermatofibrosarcoma protuberans. A study of 115 cases. Cancer1962;15:717–25, doi:10.1002/1097-0142(196207/08)15:4<717::AID-CNCR2820150405>3.0.CO;2-2.
10.
WeinsteinJMDroletBAEsterlyNB. Congenital dermatofibrosarcoma protuberans: variability in presentation. Arch Dermatol2003;139:207–11, doi:10.1001/archderm.139.2.207.
11.
JafarianFMcCuaigCKoktaV. Dermatofibrosarcoma protuberans in childhood and adolescence: report of eight patients. Pediatr Dermatol2008;25:317–25, doi:10.1111/j.1525-1470.2008.00674.x.
12.
BoguckiBNeuhausIHurstEA. Dermatofibrosarcoma protuberans: a review of the literature. Dermatol Surg2012;38:537–51, doi:10.1111/j.1524-4725.2011.02292.x.
BurkhardtBRSouleEHWinkelmannRK. Dermatofibrosarcoma protuberans. Study of fifty-six cases. Am J Surg1966;111:638–44, doi:10.1016/0002-9610(66)90031-6.
15.
CriscioneVDWeinstockMA. Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002. J Am Acad Dermatol2007;56:968–73, doi:10.1016/j.jaad.2006.09.006.
16.
Abdel WahabOQassemyarAMailletM. [Dermatofibrosarcoma protuberans in children]. Ann Chir Plast Esthet2011;57:140–6, doi:10.1016/j.anplas.2011.11.002.
Terrier-LacombeMJGuillouLMaireG. Dermatofibrosarcoma protuberans, giant cell fibroblastoma, and hybrid lesions in children: clinicopathologic comparative analysis of 28 cases with molecular data—a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol2003;27:27–39, doi:10.1097/00000478-200301000-00004.
19.
MaireGFraitagSGalmicheL. A clinical, histologic, and molecular study of 9 cases of congenital dermatofibrosarcoma protuberans. Arch Dermatol2007;143:203–10, doi:10.1001/archderm.143.2.203.
20.
CaiHWangYWuJ. Dermatofibrosarcoma protuberans: clinical diagnoses and treatment results of 260 cases in China. J Surg Oncol2012;105:142–8, doi:10.1002/jso.22000.
21.
KuzelPMetelitsaAIDoverDC. Epidemiology of dermatofibrosarcoma protuberans in Alberta, Canada, from 1988 to 2007. Dermatol Surg2012;38:1461–8, doi:10.1111/j.1524-4725.2012.02482.x.
22.
PappoASRaoBNCainA. Dermatofibrosarcoma protuberans: the pediatric experience at St. Jude Children’s Research Hospital. Pediatr Hematol Oncol1997;14:563–8, doi:10.3109/08880019709030913.
23.
MartinLCombemalePDupinM. The atrophic variant of dermatofibrosarcoma protuberans in childhood: a report of six cases. Br J Dermatol1998;139:719–25, doi:10.1046/j.1365-2133.1998.1390s2008.x.
24.
ThorntonSLReidJPapayFA. Childhood dermatofibrosarcoma protuberans: role of preoperative imaging. J Am Acad Dermatol2005;53:76–83, doi:10.1016/j.jaad.2004.11.071.
25.
Bendix-HansenKMyhre-JensenOKaaeS. Dermatofibrosarcoma protuberans. A clinico-pathological study of nineteen cases and review of world literature. Scand J Plast Reconstr Surg1983;17:247–52, doi:10.3109/02844318309013125.
26.
AbenozaPLillemoeT. CD34 and factor XIIIa in the differential diagnosis of dermatofibroma and dermatofibrosarcoma protuberans. Am J Dermatopathol1993;15:429–34, doi:10.1097/00000372-199310000-00003.
27.
KilclineCFriedenIJ. Infantile hemangiomas: how common are they? A systematic review of the medical literature. Pediatr Dermatol2008;25:168–73, doi:10.1111/j.1525-1470.2008.00626.x.
GarzonMCHuangJTEnjolrasO. Vascular malformations: part I. J Am Acad Dermatol2007;56:353–70, doi:10.1016/j.jaad.2006.05.069.
30.
FettNWerthVP. Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol2011;64:217–28, doi:10.1016/j.jaad.2010.05.045.
31.
NijhawanRIBardSBlyuminM. Early localized morphea mimicking an acquired port-wine stain. J Am Acad Dermatol2011;64:779–82, doi:10.1016/j.jaad.2009.10.017.
32.
PirouzmaneshAReinischJFGonzalez-GomezI. Pilomatrixoma: a review of 346 cases. Plast Reconstr Surg2003;112:1784–9, doi:10.1097/01.PRS.0000091160.54278.64.
33.
CroteauSELiangMGKozakewichHP. Kaposiform hemangioendothelioma: atypical features and risks of Kasabach-Merritt phenomenon in 107 referrals. J Pediatr2013;162:142–7, doi:10.1016/j.jpeds.2012.06.044.
34.
McArthurG. Dermatofibrosarcoma protuberans: recent clinical progress. Ann Surg Oncol2007;14:2876–86, doi:10.1245/s10434-007-9480-y.
35.
SirventNMaireGPedeutourF. Genetics of dermatofibrosarcoma protuberans family of tumors: from ring chromosomes to tyrosine kinase inhibitor treatment. Genes Chromosomes Cancer2003;37:1–19, doi:10.1002/gcc.10202.
36.
ShimizuAO’BrienKPSjoblomT. The dermatofibrosarcoma protuberans-associated collagen type Ialpha1/platelet-derived growth factor (PDGF) B-chain fusion gene generates a transforming protein that is processed to functional PDGF-BB. Cancer Res1999;59:3719–23.
37.
VothHLandsbergJHinzT. Management of dermatofibrosarcoma protuberans with fibrosarcomatous transformation: an evidence-based review of the literature. J Eur Acad Dermatol Venereol2011;25:1385–91, doi:10.1111/j.1468-3083.2011.04141.x.
38.
ErdemOWyattAJLinE. Dermatofibrosarcoma protuberans treated with wide local excision and followed at a cancer hospital: prognostic significance of clinicopathologic variables. Am J Dermatopathol2012;34:24–34, doi:10.1097/DAD.0b013e3182120671.
39.
BowneWBAntonescuCRLeungDH. Dermatofibrosarcoma protuberans: a clinicopathologic analysis of patients treated and followed at a single institution. Cancer2000;88:2711–20, doi:10.1002/1097-0142(20000615)88:12<2711::AID-CNCR9>3.0.CO;2-M.
40.
FieldsRCHameedMQinLX. Dermatofibrosarcoma protuberans (DFSP): predictors of recurrence and the use of systemic therapy. Ann Surg Oncol2011;18:328–36, doi:10.1245/s10434-010-1316-5.
